Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, Second Edition delves into the complexities of drug discovery, specifically for Alzheimer's Disease, presenting the necessary paradigm for future success in research and treatment. This edition is thoroughly updated with recent developments in therapeutic strategies, including amyloid hypothesis, tau, apo E, insulin, and others, and introduces a new chapter on drug delivery to the brain. Additionally, the book encompasses diagnosis, epidemiology, drug discovery strategies, current therapeutics, and more, offering a comprehensive approach to Alzheimer's Disease.
It covers the latest in targeted drug design, preclinical studies, and animal models, making it an essential resource for pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers. Patients and advocacy groups can also gain valuable insights from the overview of current treatments and scientific advancements in the field.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. xv 7. Foreword - p. xvii 8. Preface - p. xix 9. Acknowledgments - p. xxi 10. Chapter 1. Neurodegenerative disorders: Why do we need new therapies? - p. 1 11. Chapter 2. Neurocognitive assessment in Alzheimer's disease clinical research - p. 19 12. Chapter 3. National plan and resources to address alzheimer's disease - p. 35 13. Chapter 4. Current therapies for the treatment of Alzheimer's disease - p. 63 14. Chapter 5. Physicochemical properties for potential Alzheimer's disease drugs - p. 81 15. Chapter 6. Receptor targets in Alzheimer's disease drug discovery - p. 119 16. Chapter 7. Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease - p. 151 17. Chapter 8. Tau proteins - p. 197 18. Chapter 9. Cholesterol, lipid metabolism, and lipid rafts in Alzheimer's disease - p. 211 19. Cholesterol and fat metabolism in Alzheimer's disease - p. 211 20. Lipidomics as a strong tool in deciphering role of lipid moieties in AD - p. 212 21. Plasma membrane microdomain (lipid rafts) and AD - p. 216 22. Cholesterol and lipid rafts modulate APP processing and Aβ moieties generation - p. 223 23. Excitotoxicity-induced lipid alteration: A potential link between cholesterol and AD - p. 229 24. Pathological activation of neuronal SREBP1: A common denominator in neurodegenerative diseases - p. 230 25. Chapter 10. Mitochondria as a therapeutic target for the treatment of Alzheimer's disease - p. 265 26. Chapter 11. Anti-inflammatory and immunomodulating agents - p. 287 27. Chapter 12. Simple in vivo models of Alzheimer's disease - p. 327 28. Chapter 13. Use of rodent models in drug discovery for Alzheimer’s disease - p. 359 29. Chapter 14. Drug delivery to the brain - p. 375 30. Chapter 15. Drugs in clinical trials for Alzheimer's disease - p. 407 31. Chapter 16. Non-pharmacologic treatment approaches - p. 415 32. Chapter 17. The advent of computer-aided drug design, machine learning, and artificial intelligence in Alzheimer's disease drug discovery - p. 433 33. Index - p. 445
Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease, Second Edition delves into the complexities of drug discovery, specifically for Alzheimer's Disease, presenting the necessary paradigm for future success in research and treatment. This edition is thoroughly updated with recent developments in therapeutic strategies, including amyloid hypothesis, tau, apo E, insulin, and others, and introduces a new chapter on drug delivery to the brain. Additionally, the book encompasses diagnosis, epidemiology, drug discovery strategies, current therapeutics, and more, offering a comprehensive approach to Alzheimer's Disease.
It covers the latest in targeted drug design, preclinical studies, and animal models, making it an essential resource for pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers. Patients and advocacy groups can also gain valuable insights from the overview of current treatments and scientific advancements in the field.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. xv 7. Foreword - p. xvii 8. Preface - p. xix 9. Acknowledgments - p. xxi 10. Chapter 1. Neurodegenerative disorders: Why do we need new therapies? - p. 1 11. Chapter 2. Neurocognitive assessment in Alzheimer's disease clinical research - p. 19 12. Chapter 3. National plan and resources to address alzheimer's disease - p. 35 13. Chapter 4. Current therapies for the treatment of Alzheimer's disease - p. 63 14. Chapter 5. Physicochemical properties for potential Alzheimer's disease drugs - p. 81 15. Chapter 6. Receptor targets in Alzheimer's disease drug discovery - p. 119 16. Chapter 7. Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease - p. 151 17. Chapter 8. Tau proteins - p. 197 18. Chapter 9. Cholesterol, lipid metabolism, and lipid rafts in Alzheimer's disease - p. 211 19. Cholesterol and fat metabolism in Alzheimer's disease - p. 211 20. Lipidomics as a strong tool in deciphering role of lipid moieties in AD - p. 212 21. Plasma membrane microdomain (lipid rafts) and AD - p. 216 22. Cholesterol and lipid rafts modulate APP processing and Aβ moieties generation - p. 223 23. Excitotoxicity-induced lipid alteration: A potential link between cholesterol and AD - p. 229 24. Pathological activation of neuronal SREBP1: A common denominator in neurodegenerative diseases - p. 230 25. Chapter 10. Mitochondria as a therapeutic target for the treatment of Alzheimer's disease - p. 265 26. Chapter 11. Anti-inflammatory and immunomodulating agents - p. 287 27. Chapter 12. Simple in vivo models of Alzheimer's disease - p. 327 28. Chapter 13. Use of rodent models in drug discovery for Alzheimer’s disease - p. 359 29. Chapter 14. Drug delivery to the brain - p. 375 30. Chapter 15. Drugs in clinical trials for Alzheimer's disease - p. 407 31. Chapter 16. Non-pharmacologic treatment approaches - p. 415 32. Chapter 17. The advent of computer-aided drug design, machine learning, and artificial intelligence in Alzheimer's disease drug discovery - p. 433 33. Index - p. 445
